Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

Howard A "Skip" Burris, III, MD
Published: Friday, Jul 08, 2016



Howard A. “Skip” Burris, MD president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discuses the MARIANNE trial in advanced HER2-positive breast cancer.  
 
In the overall study results, patients with locally advanced or untreated metastatic HER2-positive disease were randomized to receive T-DM1 plus pertuzumab (Perjeta), T-DM1 alone, or trastuzumab (Herceptin) plus a taxane-based agent. Phase III results of the trial showed that neither T-DM1 arm was associated with improved outcomes compared with the trastuzumab/taxane arm.
 
However, in patient-reported outcomes of the trial, patients with advanced HER2-positive breast cancer who received treatment with trastuzumab emtanzssine were found to have a lower incidence of treatment-related adverse events.
 
These means that trastuzumab emtanzssine is still a good option for patients with advanced HER2-positive breast cancer, says Burris.
 


Howard A. “Skip” Burris, MD president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, discuses the MARIANNE trial in advanced HER2-positive breast cancer.  
 
In the overall study results, patients with locally advanced or untreated metastatic HER2-positive disease were randomized to receive T-DM1 plus pertuzumab (Perjeta), T-DM1 alone, or trastuzumab (Herceptin) plus a taxane-based agent. Phase III results of the trial showed that neither T-DM1 arm was associated with improved outcomes compared with the trastuzumab/taxane arm.
 
However, in patient-reported outcomes of the trial, patients with advanced HER2-positive breast cancer who received treatment with trastuzumab emtanzssine were found to have a lower incidence of treatment-related adverse events.
 
These means that trastuzumab emtanzssine is still a good option for patients with advanced HER2-positive breast cancer, says Burris.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Publication Bottom Border
Border Publication
x